Related Experiment Video
Updated: Apr 21, 2026
12:02
Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
16.6K
Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study
1Department of Newborn Services, George Washington University and Children's National Medical Center, Washington, DC, USA.
Summary
Melatonin treatment in newborns with hypoxic-ischemic encephalopathy (HIE) improved outcomes. This study found melatonin combined with hypothermia reduced brain injury and improved neurodevelopmental results in HIE infants.
Area of Science:
- Neonatal Medicine
- Neuroscience
- Biochemistry
Background:
- Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal brain injury.
- Melatonin demonstrates neuroprotective properties in preclinical models.
- Understanding melatonin's role in HIE is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the efficacy of melatonin in improving clinical, biochemical, neurophysiological, and radiological outcomes in neonates diagnosed with HIE.
- To assess the feasibility and safety of administering melatonin alongside standard hypothermia treatment for HIE.
Main Methods:
- A prospective trial involving 45 newborns (30 with HIE, 15 controls) was conducted.
- HIE infants were randomized to either hypothermia alone or combined melatonin and hypothermia treatment.
- Biochemical markers (melatonin, SOD, NO), EEG, MRI, and neurodevelopmental assessments at 6 months were utilized.
Main Results:
- The melatonin/hypothermia group showed a significant increase in serum melatonin and a decline in nitric oxide levels compared to controls.
- Fewer seizures and reduced white matter abnormalities were observed on EEG and MRI in the melatonin group.
- Infants receiving melatonin with hypothermia exhibited improved survival rates and better neurodevelopmental outcomes at 6 months.
Conclusions:
- Early administration of melatonin is a feasible adjunctive therapy for term neonates suffering from HIE.
- Melatonin may significantly ameliorate brain injury and improve long-term neurological outcomes in HIE patients.
Related Concept Videos
01:19Management of Insomnia
807
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
807
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
955
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
955